Crizotinib, a first-generation targeted TKI for advanced ALK+ NSCLC, was approved by the US Food and Drug Administration (FDA) in 2011 and has been established as the current standard of care in the US (20, 21). This evidence concerns the gene ALK and non-small cell lung carcinoma.